HSK-31858

HSK-31858 Medication Report

Name: HSK-31858 Name (English): HSK-31858

Mechanism of Action: HSK-31858 is a novel, oral, potent, and highly selective small molecule inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), including neutrophil elastase (NE), proteinase 3, and cathepsin G, during neutrophil maturation in the bone marrow. By inhibiting DPP1, HSK-31858 reduces the activation of these NSPs, which are implicated in the damaging inflammation and progression of neutrophil-mediated inflammatory diseases.

Uses: HSK-31858 is being investigated for the treatment of respiratory diseases characterized by neutrophilic inflammation. Clinical trials are ongoing for the following indications:

• Bronchiectasis: Phase 2 trials have shown that HSK-31858 significantly reduces the frequency of exacerbations and prolongs the time to the first exacerbation in adults with bronchiectasis. A Phase 3 trial is currently recruiting participants with non-cystic fibrosis bronchiectasis.
• Cystic Fibrosis: A Phase 3 trial is recruiting participants with cystic fibrosis and bronchiectasis.
• Asthma: A Phase 2 trial is enrolling participants with asthma.
• Chronic Obstructive Pulmonary Disease (COPD): A Phase 2 trial is enrolling participants with COPD and bronchiectasis.
• Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases: A Phase 2 trial is enrolling participants.